Compare AU
Compare DRUG vs. VISM
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the Vanguard MSCI International Small Companies Index ETF (VISM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | VISM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 262 |
Median incremental investment | $920.50 | $1,105.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $2,561.14 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | VISM | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | Vanguard MSCI International Small Companies Index ETF aims to track the returns and performance of the MSCI World ex-Australia Small Cap Index before considering fees, expenses, and tax. It tracks the performance of the index with dividends reinvested. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Reliance Steel & Aluminum Co. (0.20 %) United Therapeutics Corp. (0.20 %) Axon Enterprise Inc. (0.19 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Industrials (19.35 %) Financials (14.55 %) Consumer Discretionary (12.64 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (62.44 %) Japan (12.99 %) United Kingdom of Great Britain and Northern Ireland (5.56 %) |
Management fee | 0.57 % | 0.32 % |
Key Summary
DRUG | VISM | |
|---|---|---|
Issuer | BetaShares | Vanguard |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | MSCI World ex AU Small Cap |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.32 % |
Price | $7.95 | $69.22 |
Size | $185.172 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 4.37 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 13/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | VISM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 262 |
Median incremental investment | $920.50 | $1,105.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $2,561.14 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | VISM | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | VISM |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |